期刊
PAIN
卷 110, 期 1-2, 页码 400-408出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.pain.2004.04.023
关键词
analgesia; cancer pain; neurolytic celiac plexus block; neurolytic hypogastric plexus block; opioid consumption; quality of life
Neurolytic sympathetic plexus block (NSPB) has been proposed to prevent the development of pain and improve the quality of life of patients with cancer, thus questioning the WHO protocol that proposes the use of invasive methods only as a final resort. This study evaluates the pain relief, opioid consumption and quality of life provided by the use of NSPB in two different phases of cancer pain and compares them with that provided by pharmacological therapy only. Sixty patients with abdominal or pelvic cancer pain were divided into three groups and observed for 8 weeks. In group 1, neurolytic celiac (NCPB) or superior hypogastric plexus block (SHPB), or lumbar sympathetic ganglion chain block (LSGCB) was performed with alcohol in patients using NSAID and a weak oral opioid or morphine (dose less than or equal to 90 mg/day) and reporting VAS greater than or equal to 4. In group II, NCPB, SHPB or LSGCB were performed on patients using NSAID and morphine (dose greater than or equal to 90 mg/day) and reporting VAS greater than or equal to 4. The patients of group III received pharmacological therapy only. The patients of groups I and II had a significant reduction of pain (P < 0.004), opioid consumption (P < 0.02) and a better quality of life (P < 0.006) than those of group III, but no significant differences between groups I and II were seen in these aspects. Opioid-related adverse effects were significantly greater in group III (P < 0.05). The occasional neurolysis-related complications were transitory. The results suggest NSPB for the management of cancer pain should be considered earlier in the disease. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据